BEYOND THE FOB: CONSIDERATIONS FOR DEVELOPMENT OF DRUGS WITH NEUROLOGIC SIDE EFFECTS
Learn how neuro-active drugs present unique development challenges!
The development of new medications with neurologic effects and/or side effects present unique challenges for toxicologists. Rather than relying on clinical pathology and histology as the defining tools for determining MTDs and disease progression, often neurologic drugs are best defined by the clinical signs that manifest during the in-life phase of drug development preclinical studies.
Join us on-demand as Sinclair Research’s Vice President of Pharmacology and Veterinary Resources, G. Alex Wakefield, DVM, presents “Beyond the FOB: Considerations For Development of Drugs With Neurologic Side Effects.”
In our webinar, Sinclair Research will help you learn:
- The roles that proper species selection and neurological exams play in a well-managed toxicology program
- Insights to help you overcome the unique development challenges posed by neuro-active drugs
- Why clinical signs manifesting in in-life preclinical studies can better define neurological drugs
- How thoughtful clinical data collection can reduce the need for highly complex tools in your preclinical studies
About the Presenter:
A life science executive with more than 25 years of industry experience, G. Alex Wakefield, DVM is Sinclair Research’s Vice President of Veterinary Services and Pharmacology. An accomplished pharmaceutical development professional with extensive experience in the science and management of drug development, Wakefield is well-versed in discovery science, toxicology, veterinary services, business development and management roles.